Ph.D. Juris Hmelnickis
Chairman of the Board
Member of the Board/Chief Economist
Quality and R&D Director / Qualified person
Business Development Director
JSC “Kalceks” participated in the international exhibition CPhI Japan 2019 expanding cooperation in Southeast Asia region.
From 18th to 20th of March 2019, representatives of JSC “Kalceks” participated in international exhibition CPhI Japan 2019 in Tokyo with the aim of expanding cooperation opportunities, focusing directly on Southeast Asian market and promoting export of JSC “Kalceks” products to countries such as Japan, China, South Korea, Philippines and Taiwan.
Being responsible for drug and patient safety, JSC «Kalceks» develops adverse drug reaction monitoring (pharmacovigilance) in all countries, where our drugs are available.
«Kalceks» and its mother company «Grindeks» maintains single pharmacovigilance system.
Task of pharmacovigilance division is to eliminate potential risk to patients, and detect of both positive and negative new effects.
Division is guided by Good Pharmacovigilance Practice and national legislation. Received information is verified, evaluated and reported when required.
If using or administering our drugs you notice side effect, lack of efficacy or other unusual reaction, please report it in the way most convenient for you
by email: firstname.lastname@example.org or email@example.com
by post: Pharmacovigilance division, JSC Grindeks, Krustpils street 53, LV-1057, Riga, Latvia
by phone: +371 67083244 (business hours) or +371 22038854 (after business hours)
We guarantee full confidentiality of your data!
We also invite to report about cases of inappropriate drug use!
If you want to report side effects on «Kalceks» drugs, we kindly advise you to use abovementioned options or fill form at homepage of mother company «Grindeks»:
Qualified person for pharmacovigilance
Direct telephone number: +371 22038854